Register Login

Anticoagulant Therapy

Jul 13 2026
george

A LAC Assay that Resists DOAC Interference

Click Rahman M, Black KM, Sadeghi-Khomami A; An Automated Lupus Anticoagulant Assay Resistant to Anticoagulant Drugs Including DOACs and Oral FXI Inhibitors for a 2016 ISTH poster that documents an updated LAC assay. Background Direct oral anticoagulants (DOACs) and oral FXI inhibitors interfere with LAC testing by prolonging clotting times and increasing assay variability. Activated charcoal […]
read more
Comments (0)
Anticoagulant Therapy
Jul 6 2026
george

External Quality Assessment for Anti-FXa LMWH Assays

Check with your local medical library for this thought-provoking article: Favaloro EJ, Arunachalam S, Pasalic L. External quality assessment for low molecular weight heparin monitoring in the Australasia/Asia-Pacific region. Semin Thromb Hemost. 2026. doi: 10.1055/a-2900-7026. Epub ahead of print. PMID: 42398957. Abstract LMWH remains a widely used parenteral anticoagulant in hospital and outpatient settings for […]
read more
Comments (0)
Anticoagulant Therapy
Jul 4 2026
george

Are we Overusing LMWH?

A provocative open-access article posted on LinkedIn by Dr. Emmanuel Favaloro suggesting we are overusing LMWH: Gurumurthy G, Fan B, Gurumurthy J, et al. Should we focus on sustainable thromboprophylaxis and avoid overuse of low-molecular-weight heparins? Research and Practice in Thrombosis and Haemostasis, 2026; 10. DOI: 10.1016/j.rpth.2026.106794. Abstract Low-molecular-weight heparins (LMWHs) have become a near-routine prescription […]
read more
Comments (0)
Anticoagulant Therapy
May 15 2026
george

Perioperative Management of Antiphospholipid Syndrome Study

Click here for the open-access article, Paquette M, Miranda S, Xu Y, et al. Perioperative management of antithrombotic therapy in patients with thrombotic antiphospholipid syndrome. Blood Adv. 2026;10(9):3218–28. doi: 10.1182/bloodadvances.2026019610. PMID: 41843780; PMCID: PMC13136740. Abstract Patients with thrombotic antiphospholipid syndrome (APS) frequently require interruption of anticoagulation for invasive procedures; however, data to guide the perioperative […]
read more
Comments (0)
Anticoagulant Therapy
Mar 24 2026
george

Global Anticoagulant Supply

Here is an open-access editorial describing a critical worldwide shortage of safe therapeutic anticoagulants. Fan BE, Yee Tang JK, Favaloro EJ. Safeguarding global anticoagulant supply and access. J Thromb Haemost. 2026:S1538-7836(26)00134-0. doi: 10.1016/j.jtha.2026.02.017. PMID: 41791674. Abstract Anticoagulants are essential to healthcare, yet their global supply is inherently fragile. Reliance on animal-derived heparin creates vulnerability to […]
read more
Comments (0)
Anticoagulant Therapy
Mar 15 2026
george

Review and History: Protamine and Gene Therapy

Here is a provocative article available from your medical library: Thachil J. Protamine–the journey from DNA to heparin neutralization to gene therapy. Semin Thromb Hemost. 2022;48:240-243. doi: 10.1055/s-0041-1736574. PMID: 34729729. Abstract Protamine is now well recognized as a key heparin-neutralizing agent. However, protamine was discovered over a century ago, during experiments performed to uncover the […]
read more
Comments (0)
Anticoagulant Therapy
Load more

George Fritsma MS MLS

George Fritsma is a medical laboratory scientist, educator, and author. George  is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

read more

Cheat Sheets from George

Name

Questions or Comments?

Email George

Quick Question

What VWD therapeutic is NOT a replacement factor?